An observational study in Microbial Colonization, Eye Diseases and Ophthalmopathy, sponsored by Vanderbilt University Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Vanderbilt University Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 161 studies in Communicable Diseases with a site in United States — 29 open to participants now, 43 under way, none of them phase 3. Communicable Diseases · United States.
Among the 161 studies in Communicable Diseases with a site in United States, this one is the 20th largest by enrollment of the 44 observational ones that give a count, is one of 15 that started in 2023, is one of 45 observational ones, and was the 123rd registered.
628 studies on the registry are indexed under Communicable Diseases; 129 are open to participants now.
Browse Communicable Diseases studies →29 of the 161 studies in Communicable Diseases with a site in United States are open now. Recruiting first, the newest first:
AusperBio Therapeutics Inc. · Sites in United States, Canada, France and 3 more countries
Ages 18–65
Mayo Clinic · Sites in United States
Ages 18+
Vanderbilt University Medical Center · Sites in United States
Ages 18+
Johns Hopkins University · Sites in United States
Ages 0–60 · Healthy volunteers
University of Minnesota · Sites in United States, Argentina, Australia and 18 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 91 Communicable Diseases studies recruiting now, 49 (54%) set no upper age limit and 32 (35%) stop at 75 or younger; 35 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
161 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 22 · Phase 3 12 · Phase 4 6
First in 1991; this study’s year is marked. 15 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 500 is above the median of 200 across 229 observational studies indexed under Communicable Diseases.
Median enrollment 78 across the 115 interventional studies, 350 across the 44 observational. Of the 105 that completed or were terminated, 29 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 161 have an industry lead sponsor. The 10 most frequent:
Vanderbilt University Medical Center is the lead sponsor of 837 studies on the registry; 157 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 92 (73%) have results posted.
Vanderbilt University Medical Center has 4 studies filed under Communicable Diseases — fewer than ten, so there is no comparison to draw.
12 of the studies in Communicable Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04796285Brigham and Women's HospitalA Validation Study of the Lab Clasp Device: A Point of Care Sepsis Risk Monitor | 2026-12 |
| NCT05401292University of Missouri-ColumbiaSkin Preparation for Elective Foot and Ankle Surgery | 2026-12 |
| NCT07043712University of Missouri-ColumbiaEffects of Pulse Consumption, Gut Microbiome, and Appetite in Healthy Participants | 2026-12-31 |
| NCT07287332Mayo ClinicBLOOM: Pragmatic Feasibility Trial | 2027-03 |
| NCT06546020Montana State UniversityGut Microbiota-dependent Health Impacts of Haskap Berries | 2027-05 |
Add all 12 to your calendar (.ics) → With an account.
Among the 161 studies in Communicable Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this application is to illustrate the core constituents of the ocular surface microbiome, describe factors that promote colonization, and assess the ocular microbiome's role in the health of the anterior segment. We will conduct a prospective, observational cohort study, including a longitudinal analysis of the ocular microbiome in adults.
The microbiome is defined as a community of microbial organisms that reside in a specific host niche. There is a growing body of literature on the association between gut microbiome and disease entities such as inflammatory bowel disease, colon cancer and presumably an association that might influence response to treatment in some patients.
Recent data suggest the existence of a resident ocular microbiota that may play a protective role in corneal infections [1-4]. However, not much is known about the ocular microbiome and its association with disease or response to treatment. The National Eye Institute (NEI) recently hosted a symposium to discuss challenges to characterize the ocular microbiome and its role in promoting or preventing ocular diseases. One of the major challenges discussed is the lack of a normative population- based database describing the ocular microbiome.
In response the NEI as part of the Anterior segment initiative put out an RFA requesting proposals on methods of collection of biological samples and associated clinical data (e.g. demographic, residence, medications, allergies); processing of samples to extract analytes (e.g., DNA, RNA, protein, metabolites) and characterizing microorganisms in a low biomass niche, specifically the ocular surface using16S rRNA marker gene, whole metagenome sequencing (WMS), and metatranscriptomics approaches.
We anticipate there will be approximately 20% failure rate due to the low bacterial load in these samples and so we will have to collect more samples to account for the loss of data.
We estimate that 20 patients in each cohort of eyes with ocular disease - 100 total patients and 500 normal eyes will give us sufficient power to explore this topic.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
We will include subjects who meet all of the following criteria:
Exclusion Criteria:
We will exclude subjects who meet all of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
normal eyes with no ocular disease
Other: Eye swab
primary open angle glaucoma/Ocular hypertension defined as mild glaucoma which is well controlled with no more than one drop of prostaglandin use daily for the past 6 months
Other: Eye swab
non-infectious keratopathy not using any prescription medication (OTC artificial tears are acceptable)
Other: Eye swab
Dry AMD (age related macular degeneration)
Other: Eye swab
Wet AMD
Other: Eye swab
diabetic retinopathy, any stage
Other: Eye swab
This is a simple swab under the eyelids of both eyes
Normal Ocular Microbiome
Number of patients in middle Tennessee with a normal ocular microbiome by development of a normative database.
Time frame: 3 years
Whole Metagenome Sequencing Methods
Number of ocular microbial species in different age and ethnic groups by the development of whole metagenome sequencing methods optimized for low biomass samples to characterize the ocular surface (anterior segment) microbiome.
Time frame: 3 years
Novel Metatranscriptomics Analysis
Number of active microbial pathways and host epithelial gene expression profiles by novel metatranscriptomics analysis.
Time frame: 3 years
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2023 to primary completion in Sep 2026, 36 months.
Of 128 non-industry observational studies under Communicable Diseases, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 77. This study's 36 months is close to that.
Counting every sponsor, half of 142 studies reached it within 37 months; a quarter within 17 and three quarters within 94.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Sep 2027 → Sep 2026 and completion Dec 2027 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vanderbilt University Medical Center →